An employee of the Pfizer factory in Puurs. February 22, 2021. KENZO TRIBOUILLARD/AFP
STORY – The launches will multiply, with serums against bronchiolitis, Lyme disease, certain cancers. Historical giants like Sanofi are facing the rise of Pfizer and biotechs.
Bronchiolitis, flu, Lyme, shingles, acne… Vaccine launches are expected to multiply over the next decade. Pfizer promises five new ones by 2025, Sanofi ten by 2030. Moderna has committed to targeting 15 pathogens (viruses, bacteria, etc.) by 2025. GSK mentions 23 projects in clinical development …
This acceleration of R&D is unprecedented in the vaccines market. The last major innovations date back to the 2000s, with the arrival in particular in 2006 of a vaccine against the papillomavirus, then, in 2019, against Ebola. “We are on the eve of the arrival of a new wave of vaccines and combinations of vaccines which are the fruit of new technologies, notes Thomas Croisier, sector specialist at Kearney. They will make it possible to treat illnesses which were not previously covered. The needs remain enormous.” The vaccine market, which exceeded $141 billion in sales in 2021, according to the WHO (Organization…
This article is for subscribers only. You have 89% left to discover.
Want to read more?
Unlock all items immediately.
Already subscribed? Login